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Background: Despite recent successes at controlling malaria, progress has stalled
with an estimated 219 million cases and 435,000 deaths in 2017 alone. Combined
with emerging resistance to front line antimalarial therapies in Southeast Asia, there
is an urgent need for new treatment options and novel approaches to halt the
spread of malaria. Plasmodium, the parasite responsible for malaria propagates through
mosquito transmission. This imposes an acute bottleneck on the parasite population
and transmission-blocking interventions exploiting this vulnerability are recognized as
vital for malaria elimination.
Methods: 13,533 small molecules with known activity against Plasmodium falciparum
asexual parasites were screened for additional transmission-blocking activity in an
ex vivo Plasmodium berghei ookinete development assay. Active molecules were
then counterscreened in dose response against HepG2 cells to determine their
activity/cytotoxicity window and selected non-toxic representative molecules were fully
profiled in a range of transmission and mosquito infection assays. Furthermore, the
entire dataset was compared to other published screens of the same molecules against
P. falciparum gametocytes and female gametogenesis.
Results: 437 molecules inhibited P. berghei ookinete formation with an IC50 < 10 µM.
of which 273 showed >10-fold parasite selectivity compared to activity against HepG2
cells. Active molecules grouped into 49 chemical clusters of three or more molecules,
with 25 doublets and 94 singletons. Six molecules representing six major chemical
scaffolds confirmed their transmission-blocking activity against P. falciparum male
and female gametocytes and inhibited P. berghei oocyst formation in the standard
membrane feeding assay at 1 µM. When screening data in the P. berghei development
ookinete assay was compared to published screens of the same library in assays
against P. falciparum gametocytes and female gametogenesis, it was established that
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each assay identified distinct, but partially overlapping subsets of transmission-blocking
molecules. However, selected molecules unique to each assay show transmission-
blocking activity in mosquito transmission assays.
Conclusion: The P. berghei ookinete development assay is an excellent high throughput
assay for efficiently identifying antimalarial molecules targeting early mosquito stage
parasite development. Currently no high throughput transmission-blocking assay is
capable of identifying all transmission-blocking molecules.
Keywords: malaria, transmission, ookinete, drug, screening
INTRODUCTION
Malaria is still a disease of devastating medical and economic
impact affecting nearly half of the world’s population.
Plasmodium, the apicomplexan parasite responsible for
malaria has a complex life cycle requiring both vertebrate
hosts and mosquitoes. With every round of asexual replication
within the blood, a proportion of cells are triggered to undergo
an alternative developmental pathway and transform into
mosquito-transmissible male and female gametocytes. When a
mosquito bites, these gametocytes are taken up in the bloodmeal
and within minutes transform into male and female gametes
in the mosquito midgut. Fertilization ensues and the resultant
zygote develops into a motile ookinete around 22 h after feeding.
The ookinete migrates to and through the midgut wall forming
an oocyst and infecting the mosquito. Parasites then further
develop into sporozoites that migrate to the salivary glands ready
to infect a new human host.
With the exception of tafenoquine and 8-aminoquinolines, all
antimalarial drugs have been developed primarily to target the
pathogenic asexual stage of the parasite life cycle. Consequently,
they have variable activity against other parasite stages possessing
divergent cell biology (Delves M. et al., 2012; Plouffe et al., 2016).
In order to achieve local elimination and global eradication of
malaria, reducing parasite transmission is essential (Rabinovich
et al., 2017). At the point of seeking treatment, malarial patients
frequently already possess mosquito-infectious male and female
gametocyte stage parasites, therefore a patient can be treated
and “cured” of their infection but still be able to pass parasites
on to mosquitoes and perpetuate the disease (Eziefula et al.,
2013). In addition, a significant proportion of the population in
malaria-endemic areas have asymptomatic infections and harbor
submicroscopic levels of gametocytes which contribute to the
persistence of malaria. As gametocytes develop and reside within
the human host, gametocyte-targeted transmission-blocking
drugs can be administered directly to the patient (Burrows
et al., 2017). However, the reduced and divergent metabolism
of the gametocyte leaves them insensitive to most antimalarial
treatments (Delves M. et al., 2012; Plouffe et al., 2016). Given
that the mosquito bloodmeal is composed primarily of blood,
transmission-blocking drugs administered to the patient can also
access and target early mosquito stage parasite development
when the parasite “reawakens” its metabolism and displays
more targetable cell biology. However, such a strategy requires
drugs with long half-lives so that efficacious concentrations
can be maintained within every mosquito bite where infectious
gametocytes are present. Alternatively, recent data has shown
surfaces treated with the transmission-blocking antimalarial
atovaquone are effective at delivering an efficacious dose directly
to the mosquito through contact exposure (Paton et al., 2019).
In 2010, GlaxoSmithKline (GSK) reported and released the
chemical structures of 13,533 molecules from within their
compound library with activity against P. falciparum asexual
development (Gamo et al., 2010). Since then, the Tres Cantos
Antimalarial Set (TCAMS) has been extensively screened in a
range of high throughput assays against different parasite stages
(Almela et al., 2015; Raphemot et al., 2015; Miguel-Blanco et al.,
2017) and yielded new antimalarial candidate molecules (Sanz
et al., 2011; Calderón et al., 2012; Williamson et al., 2016).
To date, little is known about their activity on early parasite
development in the mosquito. Using the rodent malaria model
P. berghei and an established ex vivo ookinete development
assay (Pb ODA) which simulates the first 22 h of parasite
development in the mosquito (Delves M.J. et al., 2012), we report
the screening, identification and profiling of new transmission-
blocking molecules.
RESULTS
Screening of the TCAMS Library in the
Pb ODA
The Pb ODA introduces gametocyte-infected mouse blood
to compound-treated “ookinete medium” that simultaneously
stimulates gametogenesis ex vivo. The readout of this assay is
parasite expression of GFP under the control of an ookinete-
specific promoter (CTRP) which is detected in a fluorescence
plate reader. Therefore, this assay can measure the ability of a
compound to inhibit parasite development from the onset of
gametogenesis to ookinete formation – approximately the first
22 h of mosquito stage development.
The entire TCAMS library was screened in the Pb ODA
at 1 µM in duplicate independent experiments (Figure 1).
A relatively lenient cut-off of >50% inhibition in one or
both replicates was selected as the assay “primary-hit” criterion
to permit even weakly active compounds to be investigated.
Under these conditions, 550 compounds were identified
(Supplementary Table S1). 513 of these compounds were
available for resupply and were retested in dose response in
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FIGURE 1 | Screening Progression Cascade. The Tres Cantos Antimalarial Set (TCAMS) was screened in the P. berghei ookinete development assay (Pb ODA) at
1 µM in duplicate identifying 550 compounds showing >50% inhibition. 437 compounds were reconfirmed in dose response to have an IC50 < 10 µM. Active
compounds were counterscreened against P. falciparum asexuals and HepG2 cells. Six potent and parasite-selective compounds representing major chemical
scaffolds were selected and studied in detail.
at least triplicate independent experiments which confirmed
an IC50 < 10 µM for 437 of them. Compounds with >70%
inhibition in the primary screen exhibited a false positive
discovery rate of 4.96% (Supplementary Tables S1, S2).
Compounds with 50–69% inhibition in the primary screen,
however, showed a false positive discovery rate of 31.66%,
suggesting future Pb ODA screens should adopt a more stringent
hit criteria of >70% inhibition. One compound with a pyridone
scaffold (TCMDC-135461) exhibited a sub-nanomolar IC50
of< 0.2 nM (the lowest concentration tested in the dose response
analysis). 21 additional compounds exhibited low-nanomolar
IC50s < 100 nM and a further 162 compounds possessed
IC50s < 1 µM (Supplementary Table S2).
Initial Profiling
The molecules active against P. berghei ookinete development
were counter-screened for activity against P. falciparum
asexual development in the growth inhibition assay (GIA),
and additionally screened against HepG2 cells to determine
cytotoxicity (Supplementary Table S2). 92 compounds were
more potent against HepG2 cells than against ookinete
development and therefore were inferred to be cytotoxic
(Figure 2A). 77 compounds were slightly parasite selective (1 to
10-fold more active against ookinete development), 190 showed
good selectivity (>10 to 100-fold) and 83 were highly selective
(>100-fold). After eliminating the cytotoxic compounds, the
activity of those remaining were compared to activity in the
Pf GIA (Figure 2B). Not a single compound had greater than
8-fold selectivity for P. berghei ookinetes over P. falciparum
asexuals. Given that the TCAMS library is comprised entirely of
compounds shown to have activity against P. falciparum asexuals,
this is unsurprising; indeed 320 out of 441 compounds were more
active against asexuals than ookinete development (Figure 2B).
Chemical Clustering Analysis
Molecular frameworks and fingerprint cluster analyses were
used to structurally characterize the 437 confirmed hits,
identifying 49 clusters and 128 singletons (Figure 3 and
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FIGURE 2 | Parasite selectivity and stage specificity. IC50s of active
compounds were determined in the P. berghei ookinete development assay
(Pb ODA). (A) These were then compared to Tox50 values against HepG2
cells to determine parasite selectivity. (B) In parallel, to determine parasite
stage specificity, Pb ODA IC50s were compared to corresponding activity in
the P. falciparum asexual inhibition growth assay (Pf GIA).
Supplementary Table S2). In addition, many clusters contained
compounds that shared a common functional scaffold and
were grouped into seven different families comprising of
pyridones, cyclic diaminopyrimidines, pyridyl derivatives,
diaminopyrimidines, quinolones, tetrahydroisoquinolines,
and benzodiazoles. The majority of compounds in the
cyclic diaminopyrimidine group were found to be cytotoxic,
however, most members of the other groups showed >10-fold
parasite selectivity.
Profiling the Transmission-Blocking
Properties of Selected Molecules
Exemplar molecules from the remaining six families
showing high potency and parasite selectivity were selected
for detailed parasitological profiling: TCMDC-135461
(pyridone); TCMDC-135907 (pyridyl derivative); TCMDC-
134114 (diaminopyrimidine); TCMDC-137173 (quinolone);
TCMDC-125849 (tetrahydroisoquinoline); TCMDC-124514
(benzodiazole) (Figure 4).
The selected molecules were evaluated for their ability
to prevent mosquito transmission at 1 µM in P. berghei
standard membrane feeding assays (Pb SMFA) (Figure 5A
and Supplementary Table S3). Relative activity in the Pb
SMFA broadly matched their activity in the Pb ODA, albeit
with reduced potency. TCMDC-137173 and TCMDC-134114
both displayed low nanomolar activity in the Pb ODA
(IC50s < 60 nM). This translated into a 97–100% inhibition of
oocyst intensity at 1 µM in the Pb SMFA. TCMDC-125849,
TCMDC-135907 and TCMDC-124514 were less active in the
Pb ODA (IC50s > 250 nM) which translated into a 9–71%
inhibition of oocyst intensity at 1 µM in the Pb SMFA.
TCMDC-135461, the pyridone compound with the most potent
activity in the Pb ODA was tested in the Pb SMFA in dose
response at 1 µM, 100 nM, and 10 nM (Figure 5B and
Supplementary Table S4). At 1 µM, no oocysts were observed
in any mosquitoes. At 100 nM, oocyst intensity was reduced
by 77.9% (±11.8% standard error of the mean − SEM). At
10 nM, oocyst intensity was inhibited by 43% (±13.7% SEM).
Taken together, based upon the direct comparison of these six
compounds in the Pb ODA and Pb SMFA, it would appear that
a Pb ODA IC50 of at least ∼60 nM translates into a near-total
transmission-blockade in mosquito feeds at 1 µM and should
set the approximate threshold onward progression of molecules
in future screens.
To ensure that data obtained using a rodent malaria
parasite shows applicability to human malaria-infective
species, the six molecules were tested in an established
P. falciparum Dual Gamete Formation Assay (Pf DGFA).
The Pf DGFA evaluates the ability of test molecules to
prevent male and female gametocytes from differentiating
into gametes in vitro, which is the first step of parasite
development in the mosquito (Ruecker et al., 2014; Delves
et al., 2018). Activity in the Pf DGFA has been shown to be
highly predictive of activity in P. falciparum SMFAs which
are technically difficult and expensive to perform (Ruecker
et al., 2014; Baragaña et al., 2015). At 1 µM a diverse
range of activities was observed against male and female
P. falciparum gametocytes (Figure 5C and Supplementary
Table S4). TCMDC-135461 and TCMDC-137173 – the two
most potent compounds in the Pb ODA showed 75.4 and
76.7% inhibition of male gametocyte functional viability
respectively, but low activity against female gametocytes (27.4
and 21.0% inhibition respectively). This indicates that these
compounds are more active against male gametocytes than
female gametocytes. TCMDC-134114 gave 97.0% inhibition
of male gametocyte functional viability and was not active
against female gametocytes – suggesting a male-specific
mode of action. In contrast, TCMDC-125849 and TCMDC-
124514 showed activity against both male (65.5 and 95.6%
inhibition respectively) and female (99.3 and 90.7% inhibition
respectively) gametocytes suggesting a mode of action targeting
biochemical pathways fundamental to both gametocyte sexes.
Finally, TCMDC-135907 showed little-to-no activity in the Pf
DGFA, perhaps suggesting that this compound targets parasite
development post-gamete formation (hence active in the Pb
ODA and not Pf DGFA).
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FIGURE 3 | Compound Clustering. Compounds active in the P. berghei ookinete development assay (Pb ODA) were clustered using the FragFP algorithm and
visualized as a dendrogram. Terminal nodes represent individual compounds and linking nodes represent FragFP similarity toward the single central point in 0.1 unit
increments. Colored regions highlight compounds possessing common major scaffolds. Graphs indicate the individual parasite selectivity (HepG2 IC50/Pb ODA IC50)
of members of each scaffold.
Comparison to Other
Transmission-Blocking Assays
With regards to potential for transmission-blocking, the TCAMS
library has also been previously screened against purified
P. falciparum late stage (stages IV-V) gametocytes in an ATP
depletion assay (Pf GC-ATP) (Almela et al., 2015), and purified
P. falciparum female gametocytes in a female gametogenesis
assay (Pf FGAA) (Miguel-Blanco et al., 2017). In the Pf GC-ATP
assay, the TCAMS were initially screened at 5 µM and yielded
363 molecules with an IC50 < 10 µM, and in the Pf FGAA
they were screened at 2 µM, yielding 405 active compounds.
In parallel, both studies also performed counterscreens against
HepG2 cells for cytotoxicity. Combining these data with the Pb
ODA screen results reported here and only considering molecules
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FIGURE 4 | Parasitological profiling. Six compounds representative of each of the major chemical scaffolds (pyridones, cyclic diaminopyrimidines, pyridyl derivatives,
diaminopyrimidines, quinolones, tetrahydroisoquinolines and benzodiazoles) with potent activity against ookinetes and high parasite selectivity were selected for
profiling in the P. berghei standard membrane feeding assay (Pb SMFA) and P. falciparum Dual Gamete Formation Assay (Pf DGFA).
with a >10-fold parasite specificity in their respective assay gives
a collection of transmission-blocking molecules with a range of
different phenotypes (Figure 6 and Supplementary Table S5).
Nevertheless, molecules from all three assays have demonstrated
transmission-blocking activity in mosquito feeds (Almela et al.,
2015; Miguel-Blanco et al., 2017; Colmenarejo et al., 2018).
DISCUSSION
The TCAMS library is the largest collection of antimalarial
molecules in the public domain and has sparked several
major antimalarial drug discovery campaigns. Antimalarial
molecules that have additional transmission-blocking activity
have the potential to make a significant contribution to malaria
elimination and eradication and are prioritized for development
(Burrows et al., 2017). The Pb ODA is a simple and relatively
inexpensive assay that can characterize the transmission-blocking
activity of hundreds of molecules with the gametocyte infected
blood of a single mouse (compared to Pb SMFAs which can
evaluate ∼2 molecules per mouse). It correlates well with SMFA
data and the majority of identified molecules are also active
against P. falciparum sexual stages.
TCMDC-135461, the representative pyridone molecule
selected for profiling was the most potent molecule active in the
Pb ODA but was less active against male and female gametocytes
in the Pf DGFA. Other pyridones are known to act by targeting
the parasite respiratory chain by inhibiting cytochrome bc1
(Capper et al., 2015). Supporting this activity, mitochondrial
respiration is essential for mosquito stage parasite development
(Goodman et al., 2016) and other cytochrome bc1 inhibitors such
as atovaquone are established transmission-blocking molecules
(Fowler et al., 1995). However, phase-1 clinical trials of the
pyridone antimalarial molecule GSK932121 were halted after
it showed acute cardiotoxicity in rats, thought to be through
inhibition of mammalian cytochrome bc1 (Capper et al., 2015).
This suggests higher selectivity is required for other pyridones to
be used as orally administered antimalarials. Recently, contact
exposure of mosquitoes to atovaquone has shown to inhibit
parasite development in the mosquito (Paton et al., 2019). This
reinforces the potential of parasite cytochrome bc1 inhibitors
as transmission blocking agents. Given the extreme potency of
TCMDC-135461, indoor residual spraying and/or baited sugar
traps may be a practical, efficacious and safer method of utilizing
this class of molecules to elicit a transmission-blocking response.
TCMDC-134114, the representative diaminopyrimidine
molecule was also potent in the Pb ODA and Pb SMFA.
Interestingly it had male gametocyte-specific activity in the
Pf DGFA. The diaminopyrimidine scaffold is found in many
molecules targeting dihydrofolate reductase (DHFR), such as the
antimalarial pyrimethamine. DHFR is required for parasite folate
biosynthesis which is essential for generating the nucleotides
required for DNA replication (Heinberg and Kirkman, 2015).
Male gametogenesis requires three rounds of endomitosis to
generate eight male gametes. In addition, ookinete development
requires one round of meiosis. Therefore, activity in the Pb ODA
(which includes male gametogenesis and ookinete development)
and male-specific activity against gametocytes in the Pf DGFA
is consistent with this mode of action for TCMDC-134114.
Datamining the chemical structure of TCMDC-137173 (the
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FIGURE 5 | Activity in other transmission-blocking assays. The six selected
molecules were evaluated in the P. berghei standard membrane feeding assay
(Pb SMFA). (A) Five molecules were tested at 1 µM to confirm
transmission-blocking activity (n = 48–53 mosquitoes per treatment). Bars
represent the mean of three biological repeats, error bars indicate the
standard error of the mean (SEM) (B) The most potent compound in the Pb
ODA, TCDMC-135461, was investigated over a range of concentrations in Pb
SMFAs (n = 22–83 mosquitoes per condition). Bars represent the mean of
three biological repeats, error bars indicate the standard error of the mean
(SEM). (C) Additionally, the compounds were tested against male and female
P. falciparum gametocytes at 1 µM in the Pf DGFA. Bars represent the mean
of at least three biological repeats, error bars indicate the standard error of the
mean (SEM).
FIGURE 6 | Venn diagram comparing the TCAMS transmission-blocking
across three transmission-blocking assay. Active compounds from the
P. berghei ookinete development assay (Pb ODA) were compared with
published activity against P. falciparum late stage gametocytes and
P. falciparum female gametogenesis (Almela et al., 2015; Miguel-Blanco et al.,
2017). To ensure parasite specificity, to be classed as active in a particular
assay, parasite selectivity had to be greater than ten-fold compared to HepG2
cells (Supplementary Table S5). Where specific compounds have been
reported to block transmission in mosquito feeds, this has been mapped onto
the Venn diagram as mosquitoes. Their position on the diagram indicates their
activity profile in the three assays and the color represents Pf SMFA (Black),
Pb SMFA (White) or both (Black and White).
representative quinolone compound) revealed that it is the
established antimalarial quinolone endochin which was first
reported in 1948 (Doggett et al., 2012). Since then, several
endochin-like antimalarials have been developed, however,
poor oral bioavailability has hampered their clinical progress
(Nilsen et al., 2013; Miley et al., 2015). Like the pyridones,
TCMDC-137173/endochin targets the parasite mitochondrial
cytochrome bc1 complex and therefore displays a transmission-
blocking profile similar to TCMDC-135461. TCMDC-125849,
the representative tetrahydroisoquinoline was moderately active
in the Pb ODA with an IC50 of 268 nM. Reflecting this, it gave
only 71.4% inhibition of oocyst intensity in the Pb SMFA at
1 µM. Supporting this level of transmission-blocking activity,
2 µM TCMDC-125849 reportedly gives 100% inhibition of
oocyst intensity and total inhibition of male gametogenesis
in P. falciparum (Colmenarejo et al., 2018). The chemical
structure of TCMDC-125849 closely resembles emetine – a
known antiprotozoal compound which inhibits protein synthesis
(Toyé et al., 1977; Wong et al., 2014). Supporting this hypothesis
of targeting such a fundamental biological pathway, 1 µM
TCMDC-125849 inhibited both male and female gametogenesis
(Figure 5C). In particular, female gametogenesis was inhibited
by 99.3%. The female readout of the Pf DGFA relies on antibody
detection of female gamete expression of Pfs25, which is
held under translational repression in the female gametocyte.
Therefore, inhibition of protein synthesis by TCMDC-125849
would be predicted to strongly reduce Pfs25 expression as
observed. The representative benzodiazole TCMDC-124514 was
also moderately active in the Pb ODA with an IC50 of 397 nM
which was reflected by low inhibition of oocyst intensity (9.1%
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inhibition) in the Pb SMFA. Interestingly at 1 µM it potently
inhibited both male and female gametogenesis suggesting
it targets biology fundamental to both gametocyte sexes. In
support of this, TCMDC-124514 has been hypothesized to be
a Coenzyme A biosynthesis inhibitor (Weidner et al., 2017)
which would both affect energy and lipid metabolism – both
fundamental pathways within the parasite. The difference in
species activity suggest that TCMDC-124514 is more active
against P. falciparum than P. berghei. The representative pyridyl
derivative, TCMDC-135907 showed moderate activity in the
Pb ODA with an IC50 of 381 nM, which again was reflected
incomplete inhibition at 1 µM in the Pb SMFA. There is no data
in the literature to suggest a mode of action for this compound,
however, data presented here suggests it targets the parasite after
gamete formation.
When comparing the activities of several high throughput
transmission assays against the TCAMS collection, it is clear to
see that no single assay is sufficient to identify all transmission-
blocking molecules. Likely this is due to the distinct (but
overlapping) cell biology that they interrogate. To date, a high
throughput assay that incorporates the entire cell biology of
transmission does not exist. Therefore, to maximize the discovery
of new transmission-blocking antimalarials, it would be prudent
to use several assays and not rely on the data generated by a
single assay alone.
MATERIALS AND METHODS
Compound Handling
The TCAMS library was provided in duplicate on assay-ready 384
well plates by GSK. 50 nl of each compound in 100% DMSO was
stamped into each well with one column containing DMSO-only
(negative control) and one column containing cycloheximide at
a final assay concentration of 10 µM (positive control). Assay
plates were stored at −20◦C until used. Compounds selected
for further investigation were supplied by GSK as 10 mM stock
solutions in 100% DMSO.
P. berghei Ookinete Development Assay
(Pb ODA)
All work involving laboratory animals was performed in
accordance with the EU regulations EU Directive 86/609/EEC
and within the regulations of the United Kingdom Animals
(Scientific Procedures) Act 1986. The Pb ODA was performed
exactly as described in Delves M.J. et al. (2012). Female T0 mice
were treated with an intraperitoneal (ip) injection of 200 µl
6 mg/ml phenylhydrazine to induce hyperreticulocytosis. Three
days later, the treated mice were infected with approximately
108 parasites by ip injection of blood from a donor mouse
infected with Plasmodium berghei expressing GFP under the
control of the ookinete-specific CTRP promoter (Vlachou et al.,
2004). Three days afterward, the presence of high levels of
gametocytes were confirmed by stimulating and observing male
gametogenesis (exflagellation). A drop of blood was sampled
from the tail of each mouse and mixed with ookinete medium
(RPMI medium with 25 mM HEPES, 2 mM L-glutamine,
2 g/l sodium bicarbonate, 50 mg/l hypoxanthine and 100 µM
anthurenic acid, adjusted to pH 7.4, plus 20% FBS) under
a coverslip on a glass slide. Ten minutes later vigorously
beating exflagellation centers were observed by phase contrast
microscopy and invariably showed >10 centers per field at
×40 objective. Infected mice were anesthetized in batches
of five, rapidly exsanguinated, blood pooled and immediately
transferred to ookinete medium at a 1:20 dilution. 50 µl of
blood/medium was then rapidly dispensed into each well of
the assay plates using a Multidrop Combi automated dispenser
(Thermo Scientific) and the plates incubated in a humidified
incubator at 19◦C in the dark for 22 h. GFP fluorescence was
then measured in a fluorescence plate reader (BMG Labtech
FluoSTAR Omega) and inhibition of ookinete production
calculated in relation to the positive and negative controls
using the formula:% inhibition of ookinete production = 100 −
[(well_fluorescence − positive_control)/(negative_control −
positive_control)× 100].
Compound Clustering and
Computational Analysis
Clustering was performed following the computational methods
described in Gamo et al. (2010). Briefly, molecular frameworks
were calculated using an in-house implementation of the
algorithm described previously (Bemis and Murcko, 1996).
Compounds were also classified in chemical families using the
Daylight fingerprint methods with a Tanimoto similarity index
of 0.85, following the procedures in the Daylight Information
Systems manual (Daylight Chemical Information Systems, 2019).
The dendrogram in Figure 3 was constructed using data
obtained from the FragFP clustering algorithm performed within
OSIRIS DataWarrior Version 04.07.03 and visualized using
Cytoscape Version 3.7.1.
P. berghei Standard Membrane Feeding
Assays (Pb SMFAs)
Membrane feeding assays were performed essentially as described
in Ramakrishnan et al. (2013). Briefly, a phenylhydrazine-treated
mouse (see above) was infected with blood from a donor mouse
infected with P. berghei 507 parasites that constitutively express
GFP throughout the parasite life cycle (Janse et al., 2006). Three
days later the infected mouse was rapidly exsanguinated and the
parasite-infected blood diluted at 1:10 dilution in naïve mouse
blood pre-warmed to 37◦C. Working as quickly as possible, the
blood mix was divided into 500 µl aliquots and mixed with
test compounds or DMSO alone at appropriate concentrations
(final DMSO concentration of 0.2%) and immediately added to
plastic water-jacketed membrane feeders and fed to Anopheles
stephensi SDA 500 strain mosquitoes. After the feed, mosquitoes
were maintained at 19◦C/80% relative humidity overnight before
unfed mosquitoes were removed. Fed mosquitoes continued to
be maintained on 8% fructose (w/v)/0.05% (w/v) p-aminobenzoic
acid for 7 days before their midguts were dissected out and
oocyst burden quantified using fluorescence microscopy and
semi-automated counting analysis (Delves and Sinden, 2010).
Data presented is the mean of three independent experiments.
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P. falciparum Dual Gamete Formation
Assay (Pf DGFA)
Compounds were tested exactly as described in Ruecker et al.
(2014) in the carry-over assay format. Briefly, functionally mature
stage V male and female gametocytes were generated by seeding
P. falciparum NF54 strain asexual cultures at 1% parasitemia
and 4% hematocrit and replacing culture medium (RPMI
medium with 25 mM HEPES, 2 mM L-glutamine, 2 g/l sodium
bicarbonate, 50 mg/l hypoxanthine plus 10% human serum) daily
for 14 days whilst maintaining a constant temperature of 37◦C
and a gas mix of 3% CO2, 5%O2, 92% N2. Gametocyte cultures
were diluted to 25 million cells/ml (including erythrocytes)
and 200 µl added to each well of a round-bottomed 96 well
plate containing test compounds. Plates also contained DMSO
negative and 20 µM methylene blue positive control wells. After
a 24 h incubation at 37◦C, gametogenesis was stimulated by
transferring the gametocytes to a flat-bottomed 96 well plate
containing 10 µl of ookinete medium at room temperature.
Twenty minutes later, the emergence of male gametes was
recorded microscopically using phase contrast and×10 objective
lens. The plate was then further incubated at 26◦C for another
24 h to allow emerged female gametes to maximally express
Pfs25 on their cell surface. An anti-Pfs25 antibody (Mab 4B7)
conjugated to the Cy3 fluorophore was added to the plates
and female gametes detected by live fluorescence microscopy
at ×10 objective. Data was then processed using custom
image analysis algorithms and percent inhibition in respect to
positive (methylene blue) and negative (DMSO) controls was
calculated. Data presented is the mean of four independent
biological repeats.
P. falciparum Asexual Growth Inhibition
Assay (Pf GIA)
The asexual activity of active compounds was tested in dose
response with parasite lactate dehydrogenase (LDH) activity
used as a readout of parasite viability as described in Gamo
et al. (2010). Briefly, 3D7-strain P. falciparum asexual parasites
were diluted to 0.25% parasitemia, 2% hematocrit in culture
medium composed of RPMI medium with 25 mM HEPES,
2% D-sucrose, 0.3% L-glutamine, 150 µM hypoxanthine plus
5% albumax. 25 µl of parasite inoculum was then dispensed
into each well of a 384 well plate containing test compounds
and positive (50 µM chloroquine) and negative (DMSO)
controls. Plates were incubated for 72 h at 37◦C in a 5%
CO2, 5%O2, 90% N2 environment before being frozen at
−70◦C. Plates were then thawed and 70 µl of reaction mix
(143 mM sodium L-lactate, 143 mM 3-acetyl pyridine adenine
dinucleotide, 178.75 mM Nitro Blue tetrazolium chloride,
286 mg/ml diaphorase (2.83 U/ml), 0.7% Tween 20, 100 mM
Tris–HCl pH 8.0) was added to each well using a Multidrop
Combi automated dispenser. Plates were shaken to mix and then
absorbance at 650 nm was measured after 10 min incubation at
room temperature. Percent inhibition of asexual growth was then
calculated with respect to positive and negative controls. Data
presented is the mean of three independent biological replicates.
HepG2 Cytotoxicity Assay
The activity of active compounds against HepG2 cells was
performed as described in Delves et al. (2018). Briefly, HepG2
cells were seeded onto compound-treated 384 well plates at a
density of 2,500 cells per well in Minimal Essential Medium
(MEM) plus 10% fetal bovine serum and 1% non-essential
amino acids solution (NEAA). Cells were incubated with test
compounds or 50 µM doxorubicin (positive) and DSMO
(negative) controls at 37◦C for 48 h in a humidified 5% CO2
atmosphere. Plates were then treated with Resazurin to a final
concentration of 45 µM for 4 h. Cell viability was then measured
in a fluorescent plate reader and percent inhibition calculated
with respect to positive and negative controls.
DATA AVAILABILITY
All datasets generated for this study are included in the
manuscript and/or Supplementary Files.
ETHICS STATEMENT
The animal study was reviewed and approved by Imperial College
Animal Welfare Ethical Review Body.
AUTHOR CONTRIBUTIONS
MD, RS, F-JG, and DL designed the study. MD performed
the Pb ookinete assay. ML-M performed the chemical
clustering analysis. MD and LU performed the Pb SMFAs. AR
performed the Pf DGFA.
FUNDING
This work was supported by a grant to RS from the Medicines
for Malaria Venture (#MMV 08/2800/01). MD was funded by a
Wellcome/LSHTM ISSF Fellowship.
ACKNOWLEDGMENTS
We would like to acknowledge Mark Tunnicliff for provision of
mosquitoes and Dolores Jimenez-Alfaro for providing support in
compound handling and platemap design.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fmicb.
2019.02134/full#supplementary-material
Frontiers in Microbiology | www.frontiersin.org 9 September 2019 | Volume 10 | Article 2134
fmicb-10-02134 September 11, 2019 Time: 16:17 # 10
Delves et al. Malaria Transmission-Molecules Targeting Ookinete Development
REFERENCES
Almela, M. J., Lozano, S., Lelièvre, J., Colmenarejo, G., Coterón, J. M., Rodrigues, J.,
et al. (2015). A new set of chemical starting points with Plasmodium falciparum
transmission-blocking potential for antimalarial drug discovery. PLoS One
10:e0135139. doi: 10.1371/journal.pone.0135139
Baragaña, B., Hallyburton, I., Lee, M. C. S., Norcross, N. R., Grimaldi, R., Otto,
T. D., et al. (2015). A novel multiple-stage antimalarial agent that inhibits
protein synthesis. Nature 522, 315–320. doi: 10.1038/nature14451
Bemis, G. W., and Murcko, M. A. (1996). the properties of known drugs. 1.
molecular frameworks. J. Med. Chem. 39, 2887–2893.
Burrows, J. N., Duparc, S., Gutteridge, W. E., Hooft van Huijsduijnen, R.,
Kaszubska, W., Macintyre, F., et al. (2017). New developments in anti-malarial
target candidate and product profiles. Malar. J. 16:26. doi: 10.1186/s12936-016-
1675-x
Calderón, F., Vidal-Mas, J., Burrows, J., de la Rosa, J. C., Jiménez-Díaz, M. B.,
Mulet, T., et al. (2012). A divergent sar study allows optimization of a potent
5-ht2c inhibitor to a promising antimalarial scaffold. ACS Med. Chem. Lett. 3,
373–377. doi: 10.1021/ml300008j
Capper, M. J., O’Neill, P. M., Fisher, N., Strange, R. W., Moss, D., Ward, S. A., et al.
(2015). Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1.
Proc. Natl. Acad. Sci. U.S.A. 112, 755–760. doi: 10.1073/pnas.1416611112
Colmenarejo, G., Lozano, S., González-Cortés, C., Calvo, D., Sanchez-Garcia,
J., Matilla, J. P., et al. (2018). Predicting transmission blocking potential of
anti-malarial compounds in the mosquito feeding assay using Plasmodium
falciparum male gamete inhibition assay. Sci. Rep. 8, 7764–7764. doi: 10.1038/
s41598-018-26125-w
Daylight Chemical Information Systems, (2019). Dlight Theory Manual. Available
at: https://www.daylight.com/dayhtml/doc/theory/index.html (Accessed May
20, 2019).
Delves, M. J., Miguel-Blanco, C., Matthews, H., Molina, I., Ruecker, A., Yahiya,
S., et al. (2018). A high throughput screen for next-generation leads targeting
malaria parasite transmission. Nat. Commun. 9:3805. doi: 10.1038/s41467-018-
05777-2
Delves, M. J., Ramakrishnan, C., Blagborough, A. M., Leroy, D., Wells, T. N. C., and
Sinden, R. E. (2012). A high-throughput assay for the identification of malarial
transmission-blocking drugs and vaccines. Int. J. Parasitol. 42, 999–1006. doi:
10.1016/j.ijpara.2012.08.009
Delves, M., Plouffe, D., Scheurer, C., Meister, S., Wittlin, S., Winzeler, E. A., et al.
(2012). The activities of current antimalarial drugs on the life cycle stages of
Plasmodium: a comparative study with human and rodent parasites. PLoS Med.
9:e1001169. doi: 10.1371/journal.pmed.1001169
Delves, M. J., and Sinden, R. E. (2010). A semi-automated method for counting
fluorescent malaria oocysts increases the throughput of transmission blocking
studies. Malar. J. 9:35. doi: 10.1186/1475-2875-9-35
Doggett, J. S., Nilsen, A., Forquer, I., Wegmann, K. W., Jones-Brando, L., Yolken,
R. H., et al. (2012). Endochin-like quinolones are highly efficacious against acute
and latent experimental toxoplasmosis. PNAS 109, 15936–15941.
Eziefula, A. C., Bousema, T., Yeung, S., Kamya, M., Owaraganise, A., Gabagaya, G.,
et al. (2013). Single dose primaquine for clearance of Plasmodium falciparum
gametocytes in children with uncomplicated malaria in Uganda: a randomised,
controlled, double-blind, dose-ranging trial. Lancet Infect. Dis. 14, 130–139.
doi: 10.1016/S1473-3099(13)70268-8
Fowler, R. E., Sinden, R. E., and Pudney, M. (1995). Inhibitory activity of the anti-
malarial atovaquone (566C80) against ookinetes, oocysts, and sporozoites of
Plasmodium berghei. J. Parasitol. 81, 452–458.
Gamo, F.-J., Sanz, L. M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J.-L.,
et al. (2010). Thousands of chemical starting points for antimalarial lead
identification. Nature 465, 305–310. doi: 10.1038/nature09107
Goodman, C. D., Siregar, J. E., Mollard, V., Vega-Rodríguez, J., Syafruddin, D.,
Matsuoka, H., et al. (2016). Parasites resistant to the antimalarial atovaquone fail
to transmit by mosquitoes. Science 352, 349–353. doi: 10.1126/science.aad9279
Heinberg, A., and Kirkman, L. (2015). The molecular basis of antifolate resistance
in Plasmodium falciparum: looking beyond point mutations. Ann. N. Y. Acad.
Sci. U.S.A. 1342, 10–18. doi: 10.1111/nyas.12662
Janse, C. J., Franke-Fayard, B., and Waters, A. P. (2006). Selection by flow-sorting
of genetically transformed, GFP-expressing blood stages of the rodent malaria
parasite, Plasmodium berghei. Nat. Protoc. 1, 614–623.
Miguel-Blanco, C., Molina, I., Bardera, A. I., Díaz, B., de Las Heras, L., Lozano,
S., et al. (2017). Hundreds of dual-stage antimalarial molecules discovered
by a functional gametocyte screen. Nat. Commun. 8, 15160. doi: 10.1038/
ncomms15160
Miley, G. P., Pou, S., Winter, R., Nilsen, A., Li, Y., Kelly, J. X., et al. (2015). ELQ-300
prodrugs for enhanced delivery and single-dose cure of malaria. Antimicrob.
Agents Chemother. 59, 5555–5560. doi: 10.1128/AAC.01183-15
Nilsen, A., LaCrue, A. N., White, K. L., Forquer, I. P., Cross, R. M., Marfurt, J., et al.
(2013). Quinolone-3-diarylethers: a new class of antimalarial drug. Sci. Transl.
Med. 5:177ra37. doi: 10.1126/scitranslmed.3005029
Paton, D. G., Childs, L. M., Itoe, M. A., Holmdahl, I. E., Buckee, C. O., and
Catteruccia, F. (2019). Exposing Anopheles mosquitoes to antimalarials blocks
Plasmodium parasite transmission. Nature 567, 239–243. doi: 10.1038/s41586-
019-0973-1
Plouffe, D. M., Wree, M., Du, A. Y., Meister, S., Li, F., Patra, K., et al. (2016).
High-throughput assay and discovery of small molecules that interrupt malaria
transmission. Cell Host Microbe 19, 114–126. doi: 10.1016/j.chom.2015.12.001
Rabinovich, R. N., Drakeley, C., Djimde, A. A., Hall, B. F., Hay, S. I., Hemingway,
J., et al. (2017). malERA: an updated research agenda for malaria elimination
and eradication. PLoS Med. 14:e1002456. doi: 10.1371/journal.pmed.1002456
Ramakrishnan, C., Delves, M. J., Lal, K., Blagborough, A. M., Butcher, G., Baker,
K. W., et al. (2013). Laboratory maintenance of rodent malaria parasites.
Methods Mol. Biol. 923, 51–72.
Raphemot, R., Lafuente-Monasterio, M. J., Gamo-Benito, F. J., Clardy, J., and
Derbyshire, E. R. (2015). Discovery of dual stage malaria inhibitors with
new targets. Antimicrob. Agents Chemother. 60, 1430–1437. doi: 10.1128/AAC.
02110-15
Ruecker, A., Mathias, D. K., Straschil, U., Churcher, T. S., Dinglasan,
R. R., Leroy, D., et al. (2014). A male and female gametocyte functional
viability assay to identify biologically relevant malaria transmission-blocking
drugs. Antimicrob. Agents Chemother. 58, 7292–7302. doi: 10.1128/AAC.
03666-14
Sanz, L. M., Jiménez-Díaz, M. B., Crespo, B., De-Cozar, C., Almela, M. J., Angulo-
Barturen, I., et al. (2011). Cyclopropyl carboxamides a novel chemical class
of antimalarial agents identified in a phenotypic screen. Antimicrob. Agents
Chemother. 55, 5740–5745. doi: 10.1128/AAC.05188-11
Toyé, P. J., Sinden, R. E., and Canning, E. U. (1977). The action of
metabolic inhibitors on microgametogenesis in Plasmodium yoelii nigeriensis.
Z. Parasitenkd 53, 133–141.
Vlachou, D., Zimmermann, T., Cantera, R., Janse, C. J., Waters, A. P., and Kafatos,
F. C. (2004). Real-time, in vivo analysis of malaria ookinete locomotion and
mosquito midgut invasion. Cell. Microbiol. 6, 671–685.
Weidner, T., Lucantoni, L., Nasereddin, A., Preu, L., Jones, P. G., Dzikowski,
R., et al. (2017). Antiplasmodial dihetarylthioethers target the coenzyme A
synthesis pathway in Plasmodium falciparum erythrocytic stages. Malar. J.
16:192. doi: 10.1186/s12936-017-1839-3
Williamson, A. E., Ylioja, P. M., Robertson, M. N., Antonova-Koch, Y., Avery, V.,
Baell, J. B., et al. (2016). Open source drug discovery: highly potent antimalarial
compounds derived from the tres cantos arylpyrroles. ACS Cent. Sci. 2, 687–
701.
Wong, W., Bai, X., Brown, A., Fernandez, I. S., Hanssen, E., Condron, M., et al.
(2014). Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound
to the anti-protozoan drug emetine. eLife 3:e03080. doi: 10.7554/eLife.03080
Conflict of Interest Statement: F-JG and ML-M are employed by
GlaxoSmithKline.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2019 Delves, Lafuente-Monasterio, Upton, Ruecker, Leroy, Gamo and
Sinden. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 10 September 2019 | Volume 10 | Article 2134
